RICHARD A. GONZALEZ - 16 Feb 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
CHAIRMAN OF THE BOARD AND CEO, Director
Signature
Steven L. Scrogham, attorney-in-fact for Richard A. Gonzalez
Issuer symbol
ABBV
Transactions as of
16 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 17:06:16 UTC
Previous filing
01 Mar 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Award $0 +149,732 +30% $0.000000 652,985 16 Feb 2023 Direct F1
transaction ABBV Common Stock, $0.01 par value Award $0 +34,937 +5.4% $0.000000 687,922 16 Feb 2023 Direct F2
transaction ABBV Common Stock, $0.01 par value Award $0 +39,022 +5.7% $0.000000 726,944 16 Feb 2023 Direct F3
transaction ABBV Common Stock, $0.01 par value Award $0 +33,210 +4.6% $0.000000 760,154 16 Feb 2023 Direct F4
holding ABBV Common Stock, $0.01 par value 17,615 16 Feb 2023 By Spouse F5
holding ABBV Common Stock, $0.01 par value 5,900 16 Feb 2023 By Step-daughter F5
holding ABBV Common Stock, $0.01 par value 5,900 16 Feb 2023 By Step-son F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Award $0 +114,787 $0.000000 114,787 16 Feb 2023 Common Stock 114,787 $149.62 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F2 Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F3 Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F4 Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
F5 The reporting person disclaims beneficial ownership of these securities.
F6 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,263 on February 16, 2024, 38,262 on February 16, 2025, and 38,262 on February 16, 2026.